New and Emerging Treatment Paradigms for SCZ Symptom Management: One Size Does Not Fit All

Cognitive rehabilitation in patients with multiple sclerosis started about 20 to 25 years ago when it transitioned from predominantly patients with traumatic brain injury to other patient populations including multiple sclerosis. And over that period of time, the number of studies that have examined the efficacy of cognitive rehabilitation in MS has grown substantially. However, gaps remain and further research is needed. Dive into to learn more about cognitive rehabilitation trials for MS with Dr. Nancy Chiaravalloti, Director of the Center for Neuropsychology and Neuroscience Research and the Center for Traumatic Brain Injury Research at Kessler Foundation, who also presented a session on this topic at the ACTRIMS 2024 Forum.

A diagnosis of schizophrenia can be distressing, making clinical interventions crucial for both the patient and their family. With the assistance of an appropriate treatment plan and peer support, the patient can gain empowerment to take control of their life and pursue long-term goals. Joining Psychiatric Nurse Practitioner Ashley Baker to discuss next steps following a schizophrenia diagnosis is Dr. Morris Goldman, Associate Professor of Psychiatry at Northwestern Feinberg School of Medicine, and Dara Sanandaji, Peer Support Supervisor at the Recovery from Early Psychosis Program.

Unfortunately, when it comes to the diagnosis and treatment of schizophrenia, there is nothing to definitively give clinicians a diagnosis, so it’s important to have a clinical evaluation and rule out everything else. But once a first episode psychosis diagnosis has been made, what treatment options are available? Dive into this episode with Psychiatric Nurse Practitioner Ashley Baker who is joined by Dr. Hannah Brown, Director of the Wellness and Recovery After Psychosis Program at Boston Medical Center and Assistant Professor of Psychiatry at Boston University Chobanian and Avedisian School of Medicine.

Major depressive disorder is a mental health condition that affects millions of Americans,¹ and for the past several decades, treatment has consisted mainly of antidepressant therapy and psychotherapy.^2,3 However, many patients still don't achieve their treatment goals and there are many potential barriers to accessing treatment. Learn more about these unmet needs in major depressive disorder care that underscore the importance of finding new treatment approaches with Dr. Aderonke Pederson, Assistant Professor of Psychiatry at Harvard Medical School.

References:

1. National Institute of Mental Health. Major depression. National Institute of Mental Health. July 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/statistics/major-depression
2. National Institute of Mental Health. Depression. National Institute of Mental Health. September 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/topics/depression
3. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. American Psychiatric Association Publishing. 2010. Accessed November 10, 2023. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf

January 2024 US.UNB.X.23.00150

Alcohol use disorder, or AUD, is a rising health crisis that often goes undiagnosed. And many patients that are diagnosed with AUD do not receive appropriate pharmacologic intervention or even a referral. Join Drs. Levesque and Cowan in this case-based educational program as they provide critical diagnostic and treatment strategies for use in the office/clinic setting and the Emergency Department.

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.

This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.